10-Q: Seres Therapeutics Faces Going Concern Doubt

Seres Therapeutics reported a net loss for the period and highlighted substantial doubt regarding its ability to continue as a going concern, necessitating additional funding.

Summary

• Seres Therapeutics filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $15.3 million for the six months ended June 30, 2026, compared to a net income of $12.8 million in the same period of 2025.
• Cash and cash equivalents stood at $15.6 million as of June 30, 2026, a decrease from $45.8 million at the end of 2025.
• The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern, anticipating the need for additional funding following the first quarter of 2027.
• Significant operating expenses were incurred in research and development ($22.3 million) and general and administrative ($15.1 million) for the six months ended June 30, 2026.
• The company recorded an impairment loss of $5.8 million related to long-lived assets, specifically operating lease right-of-use assets and leasehold improvements.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's continued substantial doubt about its ability to continue as a going concern and the significant operating losses incurred.

Positives

• The company received a $25,000 Milestone Termination Payment from SPN, with $12,500 received on July 1, 2026, and the remainder expected on October 1, 2026.
• The SER-155 Phase 1b study in irEC showed that 80% of recipients achieved an immunosuppressive-free clinical response of diarrhea at Day 15.
• SER-155 in allo-HCT patients showed a 77% relative risk reduction in bacterial BSIs compared to placebo.
• The company has an extensive patent portfolio related to live biotherapeutics, extending through at least part of 2046.

Negatives

• The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern.
• For the six months ended June 30, 2026, the company incurred a net loss of $15.3 million, with an accumulated deficit of $987.7 million.
• Cash and cash equivalents decreased to $15.6 million as of June 30, 2026, from $45.8 million as of December 31, 2025.
• Research and development expenses were $22.3 million and general and administrative expenses were $15.1 million for the six months ended June 30, 2026.
• The company recorded an impairment loss of $5.8 million on long-lived assets.
• The company anticipates requiring additional funding following the first quarter of 2027.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern.
• The company will require additional funding to advance development of its product candidates and commercialize them.
• If the company is unable to raise capital or secure a partnership, it may be required to implement further cost-reduction measures or delay product development.
• The company has incurred significant losses since inception and expects to continue incurring losses for the foreseeable future.
• Clinical drug development is a risky, lengthy, and expensive process with an uncertain outcome.
• Delays or difficulties in patient enrollment for clinical trials could delay regulatory approvals.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company's ability to protect its proprietary technology and obtain sufficient patents is critical for its success.

Future Outlook

The company anticipates requiring additional funding following the first quarter of 2027 to support ongoing operations and meet obligations. Management plans to secure this funding through financing or other strategic transactions, including potential business development transactions and selling shares under its at-the-market equity offering.

Management Comments

• "Based on the Companys currently available cash resources, the $12,500 Milestone Termination Payment (as defined below in Note 3, Discontinued Operations and TSA ) received from SPN (as defined below) in July 2026, and the expected receipt of the additional $12,500 Milestone Termination Payment due from SPN in October 2026 , current and forecasted level of operations, and forecasted cash flows for the 12-month period subsequent to the date of issuance of these condensed consolidated financial statements, the Company will require additional funding to support its ongoing operations and meet its obligations as they come due."
• "We believe that the scientific and clinical data from the development of VOWST (our then product candidate SER-109 program) and the data from the SER-155 Phase 1b study in allo-HCT and the SER-155 IST in irEC (both further described below) validate our novel therapeutic approach to address unmet medical needs in oncology that can lead to interruption to patients' cancer treatment and/or mortality, and to treat I&I diseases."
• "We are actively seeking a business development transaction, which may include a partnership, to provide financial support and share in our vision to realize the clinical and commercial value of SER-155."

Industry Context

StockSavvy.ai notes that Seres Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel live biotherapeutics. The company's challenges in securing funding and its ongoing losses are common among clinical-stage biotechs, but its progress with SER-155 in specific indications like irEC and allo-HCT, along with its established platform, positions it within a growing area of therapeutic interest.

Comparison to Industry Standards

• The company's net loss of $15.3 million for the six months ended June 30, 2026, and accumulated deficit of $987.7 million are significant, reflecting the high costs associated with clinical-stage drug development, which is typical for companies in this sector.
• The need for additional funding and the resulting 'going concern' doubt are also common challenges faced by many early-stage biotechnology companies that have not yet achieved profitability or commercial product sales.
• The company's focus on live biotherapeutics places it in a novel and emerging therapeutic area, with VOWST being the first FDA-approved oral microbiome therapeutic, setting a precedent for the field.

Management Changes

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a complaint against Seres Therapeutics, Inc. and Nestl entities alleging infringement of U.S. Patent Nos. 9,433,652, 9,662,381, 9,808,519, 10,555,978, and 11,090,343 related to VOWST.

Related Party Transactions

• Accounts receivable due from SPN - related party were $25,000 thousand as of June 30, 2026.
• Accrued liabilities due to SPN - related party were $3,278 thousand as of June 30, 2026.
• TSA reimbursement income from NESA (an affiliate of SPN) was $3,490 thousand for the six months ended June 30, 2025, and $0 for the same period in 2026.
• The company recorded a $25,000 thousand gain on sale of VOWST Business related to the Milestone Termination Payment from SPN.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to the going concern warning and the need for future financing.
• Employees may be impacted by ongoing cost reduction measures, including workforce reductions.
• Potential collaborators and investors may be hesitant to engage due to the company's financial position and going concern status.
• Creditors and suppliers may face increased risk given the company's financial challenges.

Next Steps

• Continue seeking funding for the SER-155 Phase 2 study in allo-HCT.
• Evaluate next steps for the development of SER-155 in irEC with potential partners.
• Advance IND-enabling studies for SER-603.
• Advance development and manufacturing of SER-428 and design a Phase 1b trial.
• Continue development of SER-147, pending funding availability.
• Explore potential collaborations related to I&I disease programs.

Key Dates

Recommendation

While the company has promising clinical data for SER-155 and a novel platform, the significant operating losses, accumulated deficit, and explicit 'going concern' warning necessitate caution. The need for substantial additional funding in the near future presents a considerable risk. Investors should monitor progress on securing partnerships and funding, as well as clinical trial results, before considering a more aggressive stance.

Keywords

live biotherapeutics, microbiome, oncology, inflammatory and immune diseases, SER-155, clinical trials, going concern, funding